Article Text

PDF

Effect of cholinergic and anticholinergic agents on tardive dyskinesia
  1. H. L. Klawans2,
  2. R. Rubovits
  1. Division of Neurology, Michael Reese Medical Center, Chicago, Illinois, U.S.A.
  2. The Department of Psychiatry, University of Maryland, Baltimore, Maryland, U.S.A.

    Abstract

    Tardive dyskinesia, like several other choreiform disorders, is felt to be primarily related to dopaminergic activity within the striatum. Physostigmine has been demonstrated to improve the abnormal movements in patients with tardive dyskinesia while scopolamine tends to aggravate abnormal movements and in some cases elicits abnormal movement not previously observed. This evidence supports the hypothesis that anticholinergic therapy in patients prone to develop tardive dyskinesia may increase the incidence of this disorder by lowering the threshold for the appearance of these movements.

    Statistics from Altmetric.com

    Footnotes

    • 2 Address for reprints: Harold L. Klawans, Division of Neurology, Michael Reese Medical Center, Chicago, Illinois 60616, U.S.A.

    • 1 This work was supported in part by a grant from the United Parkinson Foundation, Chicago, Illinois, U.S.A.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.